Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for VXA-CoV2-1 oral pill in COVID-19. The expected timing is based on the latest available company guidance and may change.
6/13/24- $453M BARDA-Funded Project. 9/30/24- Trial initiated. 12/3/24- Sentinel cohort enrollment completion. 1/13/25- Positive DSMB review. 3/20/25- Ordered to halt its trial, except for follow-up on 400 participants. A final decision will be made within 90 days. 5/15/25- BARDA approval to initiate dosing in 10,000-participant. 5/27/25- Initiated dosing. 03/12/26:- Sentinel cohort safety data expected Early Q2 2026; topline data for all participants expected Q4 2026. 05/07/26:- Sentinel 12-month safety/immunogenicity data now expected Q2 2026; main KP.2 cohort primary data anticipated Early 2027. 07/06/26:- Reported Ph2b sentinel 12-month topline safety data. Complete study topline data anticipated in 2027. 08/06/26:- Phase 2b complete study topline efficacy and safety data expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.